文献速递心力衰竭与心肌病心律失常

肾功能不全对心力衰竭患者β受体阻滞剂疗效的影响

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究分析10项双盲安慰剂对照试验中16,740例左室射血分数<50%的心衰患者,发现eGFR每降低10 ml/min/1.73 m2全因死亡风险增加12%;在窦性心律患者中,β受体阻滞剂在eGFR 45-59和30-44 ml/min/1.73 m2亚组均降低死亡率,而房颤患者未见获益。

要点

  • eGFR每降低10 ml/min/1.73 m2,全因死亡风险独立增加12%(95%CI 10%-15%,p<0.001)。
  • 窦性心律患者中,β受体阻滞剂在eGFR 45-59亚组调整HR 0.73(95%CI 0.62-0.86,p<0.001)。
  • 窦性心律患者中,β受体阻滞剂在eGFR 30-44亚组调整HR 0.71(95%CI 0.58-0.87,p=0.001)。

核心结论

  • 左室射血分数<50%且窦性心律的心衰患者,即使存在中度或中重度肾功能不全,也应接受β受体阻滞剂治疗。

研究设计与样本

  • 对10项双盲、安慰剂对照试验中16,740例左室射血分数<50%的个体患者数据进行分析,按eGFR分层,报告意向性治疗的全因死亡率,并校正基线协变量及按心律分层。

主要发现

  • 基线中位eGFR为63(四分位距50-77)ml/min/1.73 m2;4,584例(27.4%)eGFR 45-59 ml/min/1.73 m2,2,286例(13.7%)eGFR 30-44 ml/min/1.73 m2。
  • 中位随访1.3年,eGFR与死亡率独立相关,eGFR每降低10 ml/min/1.73 m2死亡风险增加12%(95%CI 10%-15%,p<0.001)。
  • 在13,861例窦性心律患者中,β受体阻滞剂较安慰剂降低死亡率:eGFR 45-59亚组调整HR 0.73(95%CI 0.62-0.86,p<0.001),eGFR 30-44亚组调整HR 0.71(95%CI 0.58-0.87,p=0.001)。
  • 中度或中重度肾功能不全患者随访期间肾功能未见恶化,β受体阻滞剂与安慰剂不良事件无差异,随访中肾功能恶化者死亡率更高。
  • 在2,879例房颤患者中,β受体阻滞剂在任何eGFR水平均未降低死亡率。

关键数值与推荐

  • 窦性心律心衰患者eGFR 45-59 ml/min/1.73 m2:β受体阻滞剂调整HR 0.73(95%CI 0.62-0.86,p<0.001)。
  • 窦性心律心衰患者eGFR 30-44 ml/min/1.73 m2:β受体阻滞剂调整HR 0.71(95%CI 0.58-0.87,p=0.001)。
  • eGFR每降低10 ml/min/1.73 m2:全因死亡风险增加12%(95%CI 10%-15%,p<0.001)。

临床怎么用

  • 左室射血分数<50%且窦性心律的心衰患者,合并中度或中重度肾功能不全时仍应启用β受体阻滞剂。
  • 房颤心衰患者使用β受体阻滞剂未显示死亡率获益,决策需个体化。
  • 用药期间应监测肾功能,肾功能恶化提示预后不良。

局限性

  • 因排除标准,eGFR<30 ml/min/1.73 m2的严重肾功能不全患者数量不足,无法得出结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy. OBJECTIVES: This study sought to investigate patient prognosis and the efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR). METHODS: Analysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted for baseline covariates and stratified by heart rhythm. RESULTS: Median eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m2; 4,584 patients (27.4%) had eGFR 45 to 59 ml/min/1.73 m2, and 2,286 (13.7%) 30 to 44 ml/min/1.73 m2. Over a median follow-up of 1.3 years, eGFR was independently associated with mortality, with a 12% higher risk of death for every 10 ml/min/1.73 m2 lower eGFR (95% confidence interval [CI]: 10% to 15%; p < 0.001). In 13,861 patients in sinus rhythm, beta-blockers reduced mortality versus placebo; adjusted hazard ratio (HR): 0.73 for eGFR 45 to 59 ml/min/1.73 m2 (95% CI: 0.62 to 0.86; p < 0.001) and 0.71 for eGFR 30 to 44 ml/min/1.73 m2 (95% CI: 0.58 to 0.87; p = 0.001). The authors observed no deterioration in renal function over time in patients with moderate or moderately severe renal impairment, no difference in adverse events comparing beta-blockers with placebo, and higher mortality in patients with worsening renal function on follow-up. Due to exclusion criteria, there were insufficient patients with severe renal dysfunction (eGFR <30 ml/min/1.73 m2) to draw conclusions. In 2,879 patients with atrial fibrillation, there was no reduction in mortality with beta-blockers at any level of eGFR. CONCLUSIONS: Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kotecha D, Gill SK, Flather MD, et al. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. J Am Coll Cardiol. 2019. PMID: 31806133. doi:10.1016/j.jacc.2019.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。